NO328116B1 - Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom. - Google Patents

Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom. Download PDF

Info

Publication number
NO328116B1
NO328116B1 NO20003848A NO20003848A NO328116B1 NO 328116 B1 NO328116 B1 NO 328116B1 NO 20003848 A NO20003848 A NO 20003848A NO 20003848 A NO20003848 A NO 20003848A NO 328116 B1 NO328116 B1 NO 328116B1
Authority
NO
Norway
Prior art keywords
ltp
antibody
receptor
cells
tnf
Prior art date
Application number
NO20003848A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003848D0 (no
NO20003848L (no
Inventor
Jeffrey L Browning
Jeanette Thorbecke
Vincent Tsiagbe
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20003848D0 publication Critical patent/NO20003848D0/no
Publication of NO20003848L publication Critical patent/NO20003848L/no
Publication of NO328116B1 publication Critical patent/NO328116B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20003848A 1998-01-30 2000-07-27 Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom. NO328116B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7311298P 1998-01-30 1998-01-30
US7341098P 1998-02-02 1998-02-02
PCT/US1999/001928 WO1999038525A1 (en) 1998-01-30 1999-01-29 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway

Publications (3)

Publication Number Publication Date
NO20003848D0 NO20003848D0 (no) 2000-07-27
NO20003848L NO20003848L (no) 2000-10-02
NO328116B1 true NO328116B1 (no) 2009-12-14

Family

ID=26754147

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003848A NO328116B1 (no) 1998-01-30 2000-07-27 Anvendelse av inhibitorer for lymfotoksin-beta for fremstilling av farmasoytiske sammensetninger mot folikkulaert lymfom.

Country Status (24)

Country Link
EP (1) EP1051187B9 (cs)
JP (2) JP4713733B2 (cs)
KR (1) KR100622960B1 (cs)
CN (1) CN1287853C (cs)
AT (1) ATE253930T1 (cs)
AU (1) AU752710B2 (cs)
BR (1) BR9908214A (cs)
CA (1) CA2319698A1 (cs)
CZ (1) CZ301026B6 (cs)
DE (1) DE69912743T2 (cs)
DK (1) DK1051187T3 (cs)
EA (1) EA003862B1 (cs)
EE (1) EE05235B1 (cs)
ES (1) ES2211035T3 (cs)
HU (1) HU226044B1 (cs)
IL (2) IL137489A0 (cs)
IS (1) IS2254B (cs)
NO (1) NO328116B1 (cs)
NZ (1) NZ506529A (cs)
PL (1) PL203279B1 (cs)
PT (1) PT1051187E (cs)
SK (1) SK285725B6 (cs)
TR (2) TR200101693T2 (cs)
WO (1) WO1999038525A1 (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201804A2 (en) * 1999-06-28 2002-09-28 Basf Ag Method for preventing tumoral growth
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
MXPA03003144A (es) 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CN1678625A (zh) 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
WO2004016317A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
CA2496048A1 (en) * 2002-08-14 2004-02-26 Erasmus University Medical Center Rotterdam Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use

Also Published As

Publication number Publication date
ATE253930T1 (de) 2003-11-15
AU752710B2 (en) 2002-09-26
IS2254B (is) 2007-06-15
DE69912743D1 (de) 2003-12-18
HUP0102363A2 (hu) 2001-10-28
HU226044B1 (en) 2008-03-28
JP2002501902A (ja) 2002-01-22
HUP0102363A3 (en) 2004-04-28
IL137489A (en) 2010-05-31
EP1051187A1 (en) 2000-11-15
BR9908214A (pt) 2000-11-28
PT1051187E (pt) 2004-03-31
NO20003848D0 (no) 2000-07-27
EA003862B1 (ru) 2003-10-30
CZ20002751A3 (cs) 2000-12-13
IS5570A (is) 2000-07-21
NZ506529A (en) 2002-12-20
TR200002203T2 (tr) 2000-12-21
PL342063A1 (en) 2001-05-21
ES2211035T3 (es) 2004-07-01
SK285725B6 (sk) 2007-07-06
KR20010040497A (ko) 2001-05-15
CA2319698A1 (en) 1999-08-05
JP4713733B2 (ja) 2011-06-29
DK1051187T3 (da) 2004-03-08
CZ301026B6 (cs) 2009-10-14
CN1289252A (zh) 2001-03-28
EE200000446A (et) 2001-08-15
KR100622960B1 (ko) 2006-09-12
EP1051187B9 (en) 2004-08-11
IL137489A0 (en) 2001-07-24
WO1999038525A1 (en) 1999-08-05
TR200101693T2 (tr) 2002-06-21
JP2010235621A (ja) 2010-10-21
CN1287853C (zh) 2006-12-06
DE69912743T2 (de) 2004-09-23
EP1051187B1 (en) 2003-11-12
SK11302000A3 (sk) 2001-01-18
HK1029944A1 (en) 2001-04-20
AU2348899A (en) 1999-08-16
NO20003848L (no) 2000-10-02
PL203279B1 (pl) 2009-09-30
EE05235B1 (et) 2009-12-15
EA200000798A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
US8142779B2 (en) Treatment of follicular lymphomas using inhibitors of the LT pathway
JP2010235621A (ja) リンホトキシン（ｌｔ）経路のインヒビターを使用する濾胞性リンパ腫の処置
US6284236B1 (en) Cytokine that induces apoptosis
US9700606B2 (en) HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use
JP6919091B2 (ja) Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用
US20020039577A1 (en) Methods for regulating a lymphocyte-mediated immune response by blocking costimulatory signals and blocking LFA-1 mediated adhesion in lymphocytes
NO321707B1 (no) Isolert DNA som koder for et TRAIL-polypeptid og et opploselig TRAIL-polypeptid, ekspresjonsvektor, fremgangsmate for fremstilling av et TRAIL-polypeptid, isolert DNA som koder for et fusjonsprotein, fremgangsmate for fremstilling av en TRAIL-oligomer, antistoff som binder et TRAIL-polypeptid, renset TRAIL-polypeptid og opploselig TRAIL-polypeptid, oligomer, farmasoytisk preparat, farmasoytisk preparat for bruk som et medikament, farmasoytisk preparat for anvendelse ved indusering av apoptose hos malceller samt anvendelse av et TRAIL-polypeptid ved fremstilling av et medikament.
US20030223989A1 (en) CD137 agonists to treat patients with IgE-mediated conditions
NO331410B1 (no) Antistoff mot BAFF-reseptor (BCMA) som et immunoregulatorisk middel
JP2002509431A (ja) ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
JP2022532249A (ja) インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法
NO326967B1 (no) Tumornekrosefaktor-relatert ligand (TRELL), rekombinant DNA som koder for TRELL, farmasøytiske sammensetninger inneholdende slike, samt antistoff spesifikt reaktivt med TRELL
Holler et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors
HK1029944B (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
MXPA97010399A (es) Citocina que induce apoptosis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees